Sigvotatug vedotin Phase 3 failure in 2L+ NSCLC; PFE maintained at Neutral

Overview

This report is JPMorgan's event-driven commentary on Pfizer Inc., focused on the failure of sigvotatug vedotin in the 2L+ NSCLC Phase 3 trial. The report considers the result a negative event for the product, but keeps an overall neutral view on PFE stock: valuation is not high and the pipeline still has potential appeal, but more clinical data are needed for de-risking before investor sentiment can change.

Core views

The core views include: first, sigvotatug vedotin failed to show a statistically significant improvement in overall survival versus docetaxel in the 2L+ NSCLC trial; second, the full 2L+ data and 1L data in 2027 will be key to subsequent judgments of the asset's value; third, PFE's valuation at about 10x 2027e EPS is low, but most important pipeline data will not arrive until 2027 and beyond, so JPMorgan chooses to continue waiting and maintain Neutral.

Analysis framework

The report uses event-driven clinical readout analysis, combining the main Phase 3 trial results, full follow-up data from medical conferences, the readout timeline for the 1L indication, competing asset MRK sac-TMT data, and PFE's valuation level to assess the event's impact on pipeline value and investor sentiment.

Methodology notes

• Clinical trial readoutPhase 3 oncology drug efficacy assessment

  Statistically significant improvement in overall survival versus docetaxel

  The report treats the failure to achieve a statistically significant improvement in overall survival as the key point of failure for sigvotatug vedotin in the 2L+ NSCLC indication, while retaining the observation that second-line patients may have clinically meaningful benefit.

• Pipeline valuationData-driven pipeline de-risking

  Assign value to the asset only after seeing key data

  The report believes that in the context of the recent trial failure and strong competing data, investors may need to wait for the full 2L+ data and 1L data in 2027 before pricing the asset more clearly.

• Equity valuationForward EPS multiple comparison

  About 10x 2027e EPS

  JPMorgan believes PFE stock is cheaply valued, but low valuation alone is insufficient to change sentiment, and further pipeline readouts are still needed for de-risking.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• PFIZER INC (PFE.O)

  Report coverage target

  Strengths

  Valuation is considered cheap at about 10x 2027e EPS; several assets in the company's pipeline may still enhance the investment story in the future.

  Weaknesses

  Sigvotatug vedotin failed in the Phase 3 trial for 2L+ NSCLC, weakening near-term pipeline momentum.

  Comparison

  By contrast, MRK's sac-TMT already has very strong China data in the same high PD-L1 expression setting, forming a competitive benchmark for PFE's related program.

  Risks

  If subsequent 1L data, other 2026-2027 pipeline readouts, or the full 2L+ data are not ideal, investor sentiment may continue to be pressured.

• sigvotatug vedotin

  PFE pipeline asset and the core product in this event

  Strengths

  The report notes that second-line patient data suggest potentially clinically meaningful benefit.

  Weaknesses

  The overall 2L+ NSCLC trial failed to show a statistically significant improvement in overall survival versus docetaxel.

  Comparison

  Its data performance needs to be compared with assets such as MRK sac-TMT in the same high PD-L1 expression competitive environment.

  Risks

  If the full data disclosure or the 2027 1L data fail to demonstrate a clear efficacy advantage, investors may continue not to assign significant value to the asset.

Key data

• Current price$25.08PFE US, price as of June 22, 2026.
• RatingNeutralThe report explicitly states that it maintains a Neutral rating and continues to wait.
• Key clinical resultNo statistically significant improvement in overall survival versus docetaxel was shownThis corresponds to the main negative information from the sigvotatug vedotin Phase 3 trial in 2L+ NSCLC.
• Valuation metricAbout 10x 2027e EPSJPMorgan believes PFE stock looks cheap.
• Upcoming catalystsFull 2L+ data disclosure at medical conferences; 1L data expected in 2027The report believes investors will focus on these data to assess the asset's value.
• Competitive benchmarkMRK sac-TMT has very strong China data in the same high PD-L1 expression settingMRK's global Phase 3 trial PCD is January 2028, with a possible earlier interim analysis.

Impact & implications

This trial failure weakens the near-term asset narrative for sigvotatug vedotin and makes PFE's pipeline de-risking path more dependent on subsequent full data and other readouts in 2027 and beyond. For the stock, low valuation provides some support, but investor sentiment may be unlikely to improve meaningfully before data from key programs become clearer.

Risks

• The full 2L+ NSCLC data for sigvotatug vedotin may fail to change the negative interpretation of the trial failure.
• There is uncertainty around the 2027 1L data, and a poor readout would further affect the asset's value.
• Competing assets such as MRK sac-TMT have strong data, which may weigh on market expectations for PFE's related program.
• Although PFE's valuation is low, if the pipeline cannot be de-risked, investor sentiment may still struggle to improve.

What to watch

• Disclosure of the full Ph3 2L+ data at future medical conferences.
• Data for sigvotatug vedotin in the 1L setting in 2027.
• Progress of MRK sac-TMT's global Phase 3 trial, the January 2028 PCD, and a possibly earlier interim analysis.
• PFE's other pipeline readouts in 2026 and major data updates in 2027 and beyond.
• Whether the market continues to reflect PFE pipeline uncertainty through a low-valuation discount.